Polyrizon Partners with European Medical Center for NASARIX™ Study

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 5 days ago

0mins

PLRZ+1.44%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

Research Collaboration Agreement: Polyrizon has signed an agreement with a leading European university medical center to conduct a performance and characterization study of its NASARIX™ allergy blocker, aimed at validating its nasal residence time to support the assessment of its protective barrier function.
Clinical Study Design: The study will utilize repeated measurements to evaluate the retention, distribution, and persistence of NASARIX™ in the nasal cavities of healthy participants, which is expected to provide critical data for the company's future FDA submissions.
Regulatory Compliance: The research will adhere to applicable European regulatory frameworks, including Regulation (EU) 2017/745 (MDR) and Good Clinical Practice (GCP) standards, ensuring scientific rigor and compliance throughout the study.
Strategic Implications: By collaborating with a leading academic institution and an experienced CRO, Polyrizon aims to enhance data quality, strengthen its competitive position in the biotech sector, and accelerate the market introduction of its products.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PLRZ?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PLRZ

About PLRZ

Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

uniQure Shares Surge After FDA Softens Stance on Gene Therapy

3 days agoNASDAQ.COM

FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.

Polyrizon Receives Notice of U.S. Patent Application for Drug Delivery Technology

3 days agoseekingalpha

Patent Application Announcement: Polyrizon announced the receipt of a U.S. patent application notice for its Trap & Target mucoadhesive polymer technology, aimed at enhancing drug retention and absorption in nasal and oral delivery systems, potentially laying the groundwork for future product development.
Technology Application Potential: The patent application describes formulations that could support the delivery of vaccines, biologics, and anti-inflammatory drugs, indicating that Polyrizon's technology has broad application potential across various therapeutic areas, which may attract interest from the pharmaceutical industry.
Enhanced Market Competitiveness: By improving drug retention and absorption in mucosal tissues, Polyrizon's technology is expected to strengthen its competitive position in the rapidly growing nasal drug market, thereby driving future revenue growth for the company.
Strategic Partnership Intent: Polyrizon has also signed a memorandum of understanding to acquire up to a 20% stake in eVTOL firm Colugo, demonstrating its strategic focus on diversifying its business and investing in innovative technologies.